Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
medical technology company Convatec reported an 8.7% rise in revenue in the first quarter, led by 'strong' growth in its advanced wound care and infusion care business.
For the three months ended March 2021, revenue rose 8.7% to $500 million year-on-year.
Advanced Wound Care revenue was up 8.8% on a reported basis, while Ostomy Care, its second largest business was up 6.7%.
Infusion Care revenue increased 13.9%, and continence & critical care revenue was up 7.4%.
Looking ahead, the company maintained its full year outlook, citing ongoing macro uncertainties.
For 2021, organic revenue growth is expected to be between 3% and 4.5%.